Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae.
Collagen characteristics contribute to bone biomechanical properties. Yet, few studies have analyzed the independent contributions of bone mineral density (BMD) and post-translational modifications of type I collagen to whole bone strength. Thus, the aim of this study was to determine the relative contributions of BMD and both enzymatic and non-enzymatic collagen crosslink concentration to the biomechanical properties of human vertebrae. Nineteen L3 vertebrae were collected after necropsy (age 26-93; 10 males, 9 females). BMD of the vertebral body was measured by DXA, and the vertebrae were compressed to failure to assess the stiffness, failure load and work to fracture. After mechanical testing, the concentration of both enzymatic crosslinks pyridinoline (PYD), and deoxypyridinoline (DPD) as well as, and the non-enzymatic crosslinks pentosidine (PEN) were analyzed in trabecular and cortical bone by reversed-phase HPLC. The extent of aspartic acid isomerization of type I collagen C telopeptide (CTX) was evaluated by ELISA of native (alpha CTX) and isomerized (beta CTX) forms. BMD was significantly positively related with stiffness (R(2) = 0.74; P < 0.0001), failure load (R(2) = 0.69; P < 0.0001) and work to fracture (R(2) = 0.44; P = 0.002). Bivariate regression analysis showed no association between collagen traits and biomechanical properties. However, in a multiple regression model, BMD and trabecular PEN were both significantly associated with failure load and work to fracture (multiple R(2) = 0.83, P = 0.001 and R(2) = 0.67, P = 0.001, respectively). Similarly, BMD and trabecular alpha/beta CTX ratio were both associated with stiffness (multiple R(2) = 0.83, P = 0.015). These findings indicate that post-translational modifications of type I collagen have an impact on skeletal fragility.
Viguet-Carrin
S
S
INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France.
Roux
J P
JP
INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France.
Arlot
M E
ME
INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France.
Merabet
Z
Z
INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France.
Leeming
D J
DJ
Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.
Byrjalsen
I
I
Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.
Delmas
P D
PD
INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France. Electronic address: delmas@lyon.inserm.fr.
Bouxsein
M L
ML
Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
D015502:Absorptiometry, Photon / Q000379:methods; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000502:physiology; D002102:Cadaver; D024042:Collagen Type I / Q000378:metabolism*; D005260:Female; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D008159:Lumbar Vertebrae / Q000378:metabolism / Q000502:physiology* / Q000503:physiopathology; D008239:Lysine / Q000031:analogs & derivatives* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000378:metabolism / Q000503:physiopathology
D024042:Collagen Type I; D017127:Glycation End Products, Advanced; D001120:Arginine; C062187:pentosidine; D008239:Lysine